Symbol="XBIO"
AssetType="Common Stock"
Name="Xenetic Biosciences Inc"
Description="Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts."
CIK="1534525"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="40 SPEEN STREET, SUITE 102, FRAMINGHAM, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="5762600"
EBITDA="-5746008"
PERatio="None"
PEGRatio="0"
BookValue="7.75"
DividendPerShare="0"
DividendYield="0"
EPS="-2.81"
RevenuePerShareTTM="1.443"
ProfitMargin="-1.943"
OperatingMarginTTM="-2.096"
ReturnOnAssetsTTM="-0.194"
ReturnOnEquityTTM="-0.31"
RevenueTTM="2158100"
GrossProfitTTM="1160700"
DilutedEPSTTM="-2.81"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.562"
AnalystTargetPrice="40"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.615"
PriceToBookRatio="0.433"
EVToRevenue="0.117"
EVToEBITDA="1.08"
Beta="2.891"
num_52WeekHigh="8.1"
num_52WeekLow="2.401"
num_50DayMovingAverage="3.661"
num_200DayMovingAverage="4.109"
SharesOutstanding="1532600"
DividendDate="2019-06-25"
ExDividendDate="None"
symbol="XBIO"
open="3.95"
high="4.00"
low="3.80"
price="3.85"
volume="14045.00"
latest_trading_day="2023-08-30"
previous_close="3.76"
change="0.09"
change_percent="2.3936%"
aroon_positive_momentum_days="36"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="36"
Volume_recent_avg="35745"
Change_recent_avg="-0.01"
Delta_recent_avg="0.26"
Variance_recent_avg="0.13"
Change_ratio_recent_avg="-0.72"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="36"
Aroon_momentum_negative="64"
image_negative_thumbnail_id_1="1115"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0148.jpeg"
image_negative_thumbnail_id_2="1126"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0159.jpeg"
image_neutral_thumbnail_id_1="564"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0035.jpeg"
image_neutral_thumbnail_id_2="530"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0069.jpeg"
image_positive_thumbnail_id_1="603"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0105.jpeg"
image_positive_thumbnail_id_2="949"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0111.jpeg"
image_professor_thumbnail_id_1="1167"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
image_professor_thumbnail_id_2="1194"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
